Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Epi4MS

Financiado

Cerrado

Targeting the epigenome towards a better understanding of disease pathogenesis...

Targeting the epigenome towards a better understanding of disease pathogenesis and novel therapeutic strategies in Multiple Sclerosis Multiple Sclerosis (MS) is a leading cause of unpredictable and incurable progressive disability in young adults. Although the exact cause remains unknown, this immune-mediated disease is likely triggered by environmental factors... ver más

31/05/2025

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-14

ERC-2018-COG: ERC Consolidator Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

2.00M€ | Lider

NEUROTEC PHARMA

400.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2011-26216 ATLAS EPIGENETICO DEL CEREBRO HUMANO: VARIACIONES EPIGENOMIC... 157K€ Cerrado

AGL2015-67945-P BIOMARCADORES EPIGENETICOS EN ENFERMEDADES PRIONICAS 113K€ Cerrado

SOLO Single cell omics of the Oligodendrocyte Lineage in develOpm... 174K€ Cerrado

SAF2009-11491 ESCLEROSIS MULTIPLE: INTERACCIONES GEN-GEN EN LOS ESTUDIOS D... 149K€ Cerrado

PCI2021-122087-2A PATIENT-CENTERED TARGETING OF EPIGENETIC VULNERABILITIES IN... 201K€ Cerrado

BLUEPRINT A BLUEPRINT of Haematopoietic Epigenomes 40M€ Cerrado

Duración del proyecto: 75 meses Fecha Inicio: 2019-02-14
Fecha Fin: 2025-05-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple Sclerosis (MS) is a leading cause of unpredictable and incurable progressive disability in young adults. Although the exact cause remains unknown, this immune-mediated disease is likely triggered by environmental factors in genetically predisposed individuals. I propose that epigenetic mechanisms, which regulate gene expression without affecting the genetic code, mediate the processes that cause MS and that aberrant epigenetic states can be corrected, spearheading the development of alternative therapies. We will exploit the stable and reversible nature of epigenetic marks, in particular DNA methylation, to gain insights into the novel modifiable disease mechanisms by studying the target organ in a way that has not been possible before. This highly ambitious project comprises three synergistic facets formulated in specific aims to: (i) identify epigenetic states that characterize the pathogenesis of MS, (ii) prioritize functional epigenetic states using high-throughput epigenome-screens, and (iii) develop novel approaches for precision medicine based on correcting causal epigenetic states. Our unique MS biobank combined with cutting-edge methodologies to capture pathogenic cells and measure their functional states provides a rational starting point to identify MS targets. I will complement this approach with studies of the functional impact of MS targets using innovative in vitro screens, with the added value of unbiased discovery of robust regulators of specific MS pathways. Finally, my laboratory has extensive experience with animal models of MS and I will utilize these powerful systems to dissect molecular mechanisms of MS targets and test the therapeutic potential of targeted epigenome editing in vivo. Our findings will set the stage for a paradigm-shift in studying and treating chronic inflammatory diseases based on preventing and modulating aggressive immune responses by inducing self-sustained reversal of aberrant epigenetic states.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores